The Role of Kidney in Glucose Homeostasis — SGLT2 Inhibitors, a New Approach in Diabetes Treatment

Vasileios Andrianesis; John Doupis


Expert Rev Clin Pharmacol. 2013;6(5):519-539. 

In This Article

Five-year View

Given the so far development of SGLT2 inhibitors, it is expected many new agents to complete Phase III clinical trials and to be included in this novel family. It would be possible that these agents to be intergraded in the algorithm of TIIDM management not only in combination with other agents for cases of uncontrolled diabetes or due to other drug contraindications but also as initial mono therapy. The beneficial effect of weight reduction gives SGLT2 inhibitors an important advantage taking into account that weight lose improves glycemic control and other cardiovascular risk factors.